| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T603 |
0-78 |
Sentence |
denotes |
The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: |
| T604 |
79-233 |
Sentence |
denotes |
Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge) |
| T605 |
234-320 |
Sentence |
denotes |
Control group: standard therapy II, III Primary (up to 28 days): all cause mortality |
| T606 |
321-620 |
Sentence |
denotes |
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020 |
